NCT03441958 2026-03-18
ECT-001 (UM171) Expanded Cord Blood Transplant to Treat High-risk Multiple Myeloma
Ciusss de L'Est de l'Île de Montréal
Phase 1/2 Completed
Clinical Trials
28 trialsNCT05092451 2026-03-18
Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances
M.D. Anderson Cancer Center
Phase 1/2 Recruiting
NCT07463807 2026-03-18
Testing the Investigational Medication Combination of Teclistamab and Pomalidomide Compared to the Usual Treatment (Carfilzomib, Pomalidomide, and Dexamethasone) for Patients With Multiple Myeloma Who Have Relapsed Shortly After Treatment
National Cancer Institute (NCI)
Phase 1/2 Not yet recruiting
NCT07479979 2026-03-18
Study of Selinexor With Carfilzomib, Isatuximab and Dexamethasone for Patients With Relapsed and/or Refractory Multiple Myeloma
Hoosier Cancer Research Network
Phase 1/2 Not yet recruiting
NCT07477912 2026-03-17
MSTH-CAR001
Minsk Scientific-Practical Center for Surgery, Transplantation and Hematology
Phase 1/2 Recruiting
NCT07081646 2026-03-13
ALACRITY
Alexion Pharmaceuticals, Inc.
Phase 1/2 Recruiting
NCT05583617 2026-03-06
PLYCOM
Hoffmann-La Roche
Phase 1/2 Recruiting
NCT06569147 2026-03-06
Elranatamab in Patients With Relapsed or Refractory AL Amyloidosis
Brigham and Women's Hospital
Phase 1/2 Recruiting
NCT07181941 2026-03-06
Response-Based Dose Reduction of Linvoseltamab in the Treatment of Relapsed, Refractory, or Triple-Class Relapsed/Refractory Multiple Myeloma
Fred Hutchinson Cancer Center
Phase 1/2 Recruiting
NCT07454187 2026-03-06
To Evaluate the Safety of SG2918 in Patients With Relapsed/Refractory Multiple Myeloma
Hangzhou Sumgen Biotech Co., Ltd.
Phase 1/2 Not yet recruiting
NCT04094961 2026-03-05
Ixazomib + Pomalidomide + Dexamethasone In MM
Dana-Farber Cancer Institute
Phase 1/2 Active not recruiting
NCT05434689 2026-03-05
COMMANDER
University of Alabama at Birmingham
Phase 1/2 Active not recruiting
NCT06232044 2026-03-04
Testing the Combination of Two Approved Drugs and One Experimental Drug in Patients With Relapsed or Refractory Multiple Myeloma
Alliance for Clinical Trials in Oncology
Phase 1/2 Suspended
NCT07169500 2026-03-02
Clinical Study on the Safety and Efficacy of BCMA-CART±ASCT in Treating Young Multiple Myeloma Patients
Institute of Hematology & Blood Diseases Hospital, China
Phase 1/2 Recruiting
NCT04764942 2026-02-25
Selinexor, Pomalidomide, and Dexamethasone With or Without Carfilzomib for the Treatment of Patients With Relapsed Refractory Multiple Myeloma, The SCOPE Trial
Mayo Clinic
Phase 1/2 Active not recruiting
NCT06235229 2026-02-25
DURGA-3
Gracell Biotechnologies (Shanghai) Co., Ltd.
Phase 1/2 Recruiting
NCT07336472 2026-02-25
A Study of IBI3003 in Subjects With Relapsed or Refractory Multiple Myeloma
Fortvita Biologics (USA)Inc.
Phase 1/2 Not yet recruiting
NCT00378105 2026-02-24
Bortezomib, Lenalidomide and Dexamethasone Combination Therapy in Patients With Newly Diagnosed Multiple Myeloma
Dana-Farber Cancer Institute
Phase 1/2 Active not recruiting
NCT07116616 2026-02-24
A Study of mRNA-2808 in Participants With Relapsed or Refractory Multiple Myeloma
ModernaTX, Inc.
Phase 1/2 Recruiting
NCT06953960 2026-02-23
A Study to Assess Adverse Events and Change in Disease Activity of Oral ABBV-453 Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)
AbbVie
Phase 1/2 Recruiting
NCT04973605 2026-02-20
A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma
BeOne Medicines
Phase 1/2 Recruiting
NCT01297764 2026-02-19
QUAD
Hackensack Meridian Health
Phase 1/2 Active not recruiting
NCT07421856 2026-02-19
Phase I/II Study of SENL103 for Relapsed or Refractory Multiple Myeloma: A Multicenter, Open-Label, Single-Arm Trial.
Hebei Senlang Biotechnology Inc., Ltd.
Phase 1/2 Not yet recruiting
NCT05199311 2026-02-18
Carfilzomib, Iberdomide (CC-220) and Dexamethasone (KID) in Transplant Eligible Multiple Myeloma
Hackensack Meridian Health
Phase 1/2 Recruiting
NCT06105554 2026-02-18
Phase I/II Open Label Study of Belumosudil Mesylate Alone, and in Combination With Dexamethasone, in Patients With Relapsed/Refractory Multiple Myeloma
M.D. Anderson Cancer Center
Phase 1/2 Recruiting
NCT07410494 2026-02-18
SELECT-CAR-NK
Essen Biotech
Phase 1/2 Recruiting
NCT05145816 2026-02-17
Phase 1/2a Study of Belantamab Mafodotin in Relapsed or Refractory AL Amyloidosis
University of Texas Southwestern Medical Center
Phase 1/2 Recruiting
NCT06892522 2026-02-17
A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving Etentamig (ABBV-383) as an Intravenous (IV) Infusion Alone or in Combination With Oral, IV, Subcutaneous Daratumumab; Lenalidomide; Dexamethasone; Carfilzomib
AbbVie
Phase 1/2 Recruiting